98%
921
2 minutes
20
Cisplatin, which kills cancer cells mainly through DNA crosslinking, has been widely used as a first-line chemotherapeutic agent although it also causes severe side effects. To improve anticancer outcomes, various types of cisplatin-based nanomedicines have been developed, either through direct incorporation or coordination of cisplatin within nanoparticles (NPs). During the formulation and characterization of cisplatin-loaded NPs, quantitative determination of cisplatin is crucial for both clinically used and newly developed NPs. While NPs facilitate cisplatin delivery, the use of different nanomaterials inevitably complicates its determination and increases the cost of quantification. Currently, there is still a significant demand for an accurate, simple, and cost-effective method to determine cisplatin in NPs, which would facilitate the screening and quality control of cisplatin-based nanomedicines. This review aims to discuss the main strategies for quantifying cisplatin, following a summary of the main types of cisplatin-loaded NPs. Application examples of cisplatin determination in NPs are provided, and the key features of each quantification strategy are compared. In addition, NP-based electrochemical sensors are included as an emerging approach for characterizing cisplatin loaded in NPs. Rational selection of an appropriate cisplatin determination method for NPs according to the quantification principle and specific drug-delivery settings is highly recommended.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12110417 | PMC |
http://dx.doi.org/10.3390/bios15050293 | DOI Listing |
Transl Oncol
September 2025
Université Paris Cité, Thoracic Oncology Department & CIC1425, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; U830 INSERM "Cancer, Heterogeneity, Instability, Plasticity, A.R.T group", Curie Institute, Paris, France. Electronic address: gerard.zalcma
We investigated whether angiogenesis-related microRNAs (miRNAs) predict survival in patients with pleural mesothelioma (PM) treated with bevacizumab plus pemetrexed-platinum chemotherapy in the Mesothelioma Avastin Cisplatin Pemetrexed Study ('MAPS', NCT00651456) phase 3 trial phase III trial (NCT00651456). Twelve miRNAs were measured in FFPE samples from 236 of the 448 MAPS trial patients (50.8 %), normalized to RNU48.
View Article and Find Full Text PDFDNA Repair (Amst)
August 2025
Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Radiotherapy, Erasmus MC Cancer Institute, Erasmus University Med
DNA crosslink-inducing drugs are widely used in clinical settings for treatment of solid tumors. Double strand breaks (DSBs) that arise during interstrand crosslink (ICL) repair are crucial determinants of the therapeutic response, as they lead to cell death if not repaired. DSBs can be repaired through non-homologous end joining (NHEJ), theta-mediated end joining (TMEJ), and homologous recombination (HR).
View Article and Find Full Text PDFJ Gastroenterol
September 2025
Department of Gastroenterology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-ku, Yokohama, 241-0815, Japan.
Background: Systemic chemotherapy with gemcitabine plus S-1 (GEM + S-1), GEM + CDDP plus S-1 (GEM + CDDP + S-1), or gemcitabine plus cisplatin (GEM + CDDP) is standard treatment for advanced biliary tract cancer (aBTC). We aimed to evaluate the efficacy and safety of combination chemotherapy in older patients with aBTC.
Methods: This multicenter prospective observational study (JON2104-B, UMIN000045156) included patients aged ≥ 70 years with aBTC.
Cancer Med
September 2025
Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Background: Cisplatin is a commonly used chemotherapeutic across numerous cancer types that can cause neurotoxicities in patients, including peripheral sensory neuropathy, tinnitus, hearing loss, and vertigo.
Objective: We aimed to evaluate, for the first time, how genetic ancestry impacts cisplatin-induced neurotoxicities and if disparities are related to population differences in allele frequency.
Methods: In a cohort of cisplatin-treated testicular cancer survivors, relationships between genetic ancestry and neurotoxicities, medications, and lifestyle factors were assessed using logistic regression and Kruskal-Wallis tests and multiple pairwise comparisons using the Wilcoxon rank-sum test (Benjamini-Hochberg adjustment).
J Ethnopharmacol
September 2025
School of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, 050200, China; Hebei International Cooperation Center for Ion Channel Function and Innovative Traditional Chinese Medicine, Shijiazhuang, 050091, China. Electronic address:
Ethnopharmacological Relevance: Cisplatin is widely used in chemotherapy, but hepatotoxicity limits its effectiveness. Liquiritin has liver-protective effects, but its mechanisms have not been elucidated in combination with cisplatin for liver-injury treatment in mice.
Aim Of The Study: This investigation explored liquiritin's protective effect against cisplatin-induced liver damage in mice and its mechanisms.